CHU Toulouse-Rangueil

Toulouse 31400

1 studies enrolling now · 6 studies all time

What they study most

BRAF V600E-mutant Metastatic Colorectal Cancer, Colorectal Neoplasms, Coronary Restenosis, Diabetes Mellitus, Type 2, PFO, Patent Foramen Ovale, Stroke

Studies at this site

• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer — Recruiting now
• Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer — Completed
• Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion — Running, not enrolling
• SELUTION SLR™ 014 In-stent Restenosis — Running, not enrolling
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy — Completed